Through collaborative efforts with multiple industry partners, Celerus Diagnostics has successfully demonstrated Rapid ISH™ (in-situ hybridization) on its forthcoming Wave RPD System. In-situ hybridization uses a labeled complementary DNA or RNA strand to localize a specific sequence in a section of tissue. This is distinct from immunohistochemistry which localizes proteins in tissue sections.
“The combination of on-board heating and our proprietary Wave technology has dramatically improved hybridization efficiencies for ISH assays,” said Marc Key, Chief Scientific Officer.
“We’ve had success with both fluorescent and chromogenic markers,” said Jason Lusk, Vice President of Business Development. “This is significant because the importance of molecular targets as companion diagnostics to identify patients for drug therapies continues to grow.”
Celerus Diagnostics will launch the Wave RPD System, a totally automated immunohistochemistry (IHC) and in-situ-hybridization (ISH) staining system to the market this year. The new system will be introduced at the United States and Canadian Association of Pathologists annual meeting being held in Washington DC, March 22–24.
“We continue to expand the capabilities of our core rapid incubation technology by adding on-board heating and subsequently applying it to a broadening array of protein and molecular assays,” CEO Dave Gross added.
In 2008 Celerus Diagnostics introduced Rapid IHC® with its Wave System, a semi-automated platform that delivers high-quality IHC results in 15 minutes. The addition of on-board pretreatment steps to the existing 15-minute staining protocols, results in totally automated IHC in one hour, compared to industry standards of two-and-a-half to four hours. “The combination of on-board heating and our proprietary Wave technology has dramatically improved hybridization efficiencies for ISH assays,” said Marc Key, Chief Scientific Officer.
Source: Celerus Diagnostics
